Detection of circulating tumor cells in patients with urothelial cancer

Approximately 50% of patients with metastatic urothelial cancer (UC) respond to chemotherapy and several months of therapy is required to assess for radiographic response. Blood-based biomarkers may identify patients in whom a specific therapy provides clinical benefit, and this study sought to characterize circulating tumor cells (CTCs) in patients with metastatic UC.Peripheral blood from patients with metastatic UC was evaluated for CTCs using...